Literature DB >> 26526071

The effects of pulmonary diseases on histologic types of lung cancer in both sexes: a population-based study in Taiwan.

Jing-Yang Huang1, Zhi-Hong Jian2, Oswald Ndi Nfor3, Wen-Yuan Ku4, Pei-Chieh Ko5, Chia-Chi Lung6,7, Chien-Chang Ho8, Hui-Hsien Pan9,10, Chieh-Ying Huang11, Yu-Chiu Liang12, Yung-Po Liaw13,14.   

Abstract

BACKGROUND: The associations between pulmonary diseases (asthma, chronic obstructive pulmonary disease [COPD], and tuberculosis [TB]) and subsequent lung cancer risk have been reported, but few studies have investigated the association with different histologic types of lung cancer.
METHODS: Patients newly diagnosed with lung cancer from 2004 to 2008 were identified from the National Health Insurance Research Database in Taiwan. Histologic types of lung cancer were further confirmed using the Taiwan Cancer Registry Database. Cox proportional hazards regression was used to calculate the hazard ratio (HR) of asthma, COPD, and TB and to estimate the risk of specific types of lung cancer.
RESULTS: During the study period, 32,759 cases of lung cancer were identified from 15,219,024 insurants aged 20 years and older. In men and women, the adjusted HR estimates of squamous cell carcinoma were respectively 1.37 (95 % confidence interval [CI], 1.21-1.54) and 2.10 (95 % CI, 1.36-3.23) for TB, 1.52 (95 % CI, 1.42-1.64) and 1.50 (95 % CI, 1.21-1.85) for asthma, and 1.66 (95 % CI, 1.56-1.76) and 1.44 (95 % CI, 1.19-1.74) for COPD. Similarly, the adjusted HR estimates of adenocarcinoma were respectively 1.33 (95 % CI, 1.19-1.50) and 1.86 (95 % CI, 1.57-2.19) for TB, 1.13 (95 % CI, 1.05-1.21) and 1.18 (95 % CI, 1.09-1.28) for asthma, and 1.50 (95 % CI, 1.42-1.59) and 1.33 (95 % CI, 1.25-1.42) for COPD. The HRs of small cell carcinoma were respectively 1.24 (95 % CI, 1.01-1.52) and 2.23 (95 % CI, 1.17-4.25) for TB, 1.51 (95 % CI, 1.35-1.69) and 1.63 (95 % CI, 1.16-2.27) for asthma, and 1.39 (95 % CI, 1.26-1.53) and 1.78 (95 % CI, 1.33-2.39) for COPD.
CONCLUSIONS: Asthma, COPD, and TB were associated with an increased risk of all major subtypes of lung cancer. The risk was the highest among women with TB.

Entities:  

Mesh:

Year:  2015        PMID: 26526071      PMCID: PMC4630937          DOI: 10.1186/s12885-015-1847-z

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


Background

Lung cancer is the second leading diseases contributing to years of life lost because of premature mortality [1]. Among histologic types of lung cancer, adenocarcinoma is the most common subtype in Asians but not in Europeans [2, 3]. Typical risk factors for lung cancer include smoking and exposure to arsenic, chromium, radon, or air pollution [4, 5]. Smoking is the major risk factor for lung cancer, particularly squamous cell carcinoma (SqCC) [6]. However, a previous study demonstrated that most Taiwanese women with lung cancer are non-smokers [7]. A vast majority of smokers do not seem to develop lung cancer. Although smoking is a potential risk factor, other factors may also be linked to the increased risk of lung cancer. Recent studies have concluded that chronic inflammation may be linked to lung carcinogenesis [8]. Among intrinsic pulmonary diseases, chronic obstructive pulmonary disease (COPD) [9, 10], asthma [11], and tuberculosis (TB) [12] are associated with lung cancer. Smokers with COPD have a higher risk of SqCC [13, 14]. Asthma is associated with an increased risk of SqCC and small cell carcinoma (SmCC) but is weakly associated with adenocarcinoma [15, 16]. TB is also associated with an increased risk of SqCC and adenocarcinoma but not SmCC [17]. An association between TB and lung adenocarcinoma has been reported in non-westernized countries [18]. Furthermore, the association of lung cancer with diabetes [19] and dyslipidemia [20-22] has been reported. Data on pulmonary diseases and specific histologic types of lung cancer are considerable limited in Taiwan. For a detailed evaluation of the relationship between pulmonary diseases and histologic types of lung cancer, a population-based cohort study is highly desirable. However, few such studies have been conducted. This study assessed whether pulmonary diseases are associated with an increased risk of specific types of lung cancer.

Methods

Database

The National Health Insurance Research Database (NHIRD) contains enrollment files, claims data, catastrophic illness files, and treatment registries. The national health insurance program covers more than 99 % of the population of Taiwan. The NHIRD is one of the largest administrative health care databases that is broadly used in academic studies [23-25]. This study used the linked databases of the NHIRD, Taiwan Cancer Registry Database (TCRD), and National Death Registry Database (NDRD) with the permission of the Department of Statistics, Ministry of Health and Welfare of Taiwan. The source data was encrypted and the data extracted was anonymous. This study was approved by the Institutional Review Board of the Chung-Shan Medical University Hospital, Taiwan.

Identification of Patients With Lung Cancer

In this study, 17,859,318 residents aged 20 years and older were initially enrolled. We excluded patients diagnosed with lung cancer before 2003 (n = 39,623) and those with incomplete information on sex (n = 2,600,565), registry data (n = 5), and death (n = 101). Finally, 15,219,024 patients (8,002,536 men and 7,216,488 women) were enrolled in this study. Patients newly diagnosed with lung cancer in 2004 were followed up until death, loss to follow-up, or the study end in 2008. Lung cancer was identified using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 162. Furthermore, histologic types of lung cancer were confirmed using the TCRD. The registry contains data on cancer types, initial tumor stages, and histology. Lung cancer was identified using the ICD-9-CM code 162 or ICD 10 codes C34.0, C34.1, C34.2, C34.3, C34.8, and C34.9 in the TCRD. Morphological diagnoses were determined using the ninth revision of the International Classification of Diseases for Oncology (ICD-O) on the basis of the following ICD-O codes: 80522, 80523, 80702, 80703, 80713, 80723, 80733, 80743, 80763, 80823, 80833, and 80843 for lung SqCC; 80503, 81402, 81403, 81413, 81433, 82113, 82503, 82513, 82523, 82553, 82603, 83103, 83233, 84603, 84803, 84813, 84903, and 85003 for adenocarcinoma; 80023, 80412, 80413, 80423, 80433, 80453, and 94733 for SmCC; and 80123, 80143, 80203, 80213, 80303, and 80313 for large cell carcinoma. The linked databases were used to retrieve information on the age of lung cancer diagnosis, follow-up time (in person-years), and survival time and to minimize potentially unconfirmed cancer diagnoses.

Variables of Exposure

Baseline variables included age, sex, urbanization level, geographical area, low income, and comorbidities. To reduce bias, the diagnoses of pulmonary diseases and comorbidities were confirmed by more than two outpatient visits or one admission between 2001 and 2003. Pulmonary diseases and comorbidities were defined using the following ICD-9-CM codes: asthma (493), COPD (490, 491, 492, 494, and 496), TB (010 – 012, and137.0), chronic kidney disease (585 and 586), type II diabetes mellitus (250, which excludes type I diabetes mellitus), and hyperlipidemia (272). Smoking, a major risk factor for lung cancer, COPD, and other cancer types are not available in the NHIRD [26, 27]; hence, this prevented direct adjustment for all possible confounders. However, smoking -related cancers such as lip, oral cavity, nasal cavity, pharynx, larynx, esophagus (ICD-9-CM codes: 140–150 and 160–161), pancreas (ICD-9-CM code 157), kidney, and bladder cancers (ICD-9-CM codes 188 and 189) were adjusted [28].

Statistical Analyses

All statistical analyses were conducted using the SAS statistical package (Version 9.3; SAS Institute, Inc., Cary, NC). The characteristics of the study population were compared using the chi-square test. A p value of < 0.05 was statistically significant. To evaluate the effect of age, patients were classified according to sex and age (20–39, 40–49, 50–59, 60–69, 70–79, and ≥80 years). All cities and towns were divided into three urbanization levels: low, medium, and high. The Cox proportional hazards regression model was used to estimate the hazard ratios (HRs) of histologic types of lung cancer while controlling for age, geographical area, urbanization level, low income, and comorbidities.

Results

During the study period, 32,759 cases of lung cancer were identified. Of all patients diagnosed, 47.3 % had adenocarcinoma (M: F, 8,778: 6,712), 20.3 % had SqCC (5,877: 760), 9.2 % had SmCC (2,751: 268), 0.7 % had large cell carcinoma (183: 57), and 23.2 % had other diseases (5,283: 2,090). The demographic characteristics and comorbidities of the study population are displayed in Table 1. Patients with lung cancer had higher rates of asthma, COPD, TB, hyperlipidemia, diabetes, chronic kidney disease, and smoking-related cancer than individuals without lung cancer did.
Table 1

Characteristics of the Study Population

Lung cancer (N = 32759)Non-lung cancer(N = 15186265)p-value
Lung diseases (%)
 Tuberculosis1052 (3.2)110469 (0.7)< 0.001
 Asthma4380 (13.4)747889 (4.9)< 0.001
 COPD7883 (24.1)1201101 (7.9)< 0.001
Sex (%)< 0.001
 Men22872 (69.8)7979664 (52.6)
 Women9887 (30.2)7206601 (47.4)
Age (years, %)< 0.001
 20–391049 (3.2)7221512 (47.6)
 40–493580 (10.9)3464916 (22.8)
 50–595937 (18.1)2209547 (14.6)
 60–697374 (22.5)1036090 (6.8)
 70–7910544 (32.2)823322 (5.4)
 ≧804275 (13.1)430878 (2.8)
Low income (%)a889 (2.7)245045 (1.6)< 0.001
Comorbidities (%)
 Diabetes5680 (17.3)1060714 (7.0)< 0.001
 Hyperlipidemia5988 (18.3)1347931 (8.9)< 0.001
 Chronic kidney disease961 (2.9)149730 (1.0)< 0.001
 Smoking-related cancersb777 (2.4)103201 (0.7)< 0.001
Geographical area (%)< 0.001
 Taipei City9236 (28.2)4851844 (32.0)
 North3920 (12.0)1961790 (12.9)
 Central6393 (19.5)2936377 (19.3)
 South6614 (20.2)2366398 (15.6)
 Kaohsiung-Pingtung5489 (16.8)2628117 (17.3)
 East1107 (3.3)441739 (2.9)
Urbanization (%)< 0.001
 High13889 (42.4)7519048 (49.5)
 Mid12338 (37.7)5575331 (36.7)
 Low6532 (19.9)2091866 (13.8)
Death in 2004–2008 (%)27718 (84.6)648922 (4.3)< 0.001
Follow-up time8450573801819
 (person-year)
Histologic type (%)
 Squamous cell carcinoma6637 (20.3)
 Adenocarcinoma15490 (47.3)
 Small cell carcinoma3019 (9.2)
 Large cell carcinoma240 (0.7)
 Others7373 (22.5)

aIncome is lower than the level required for charging premium

bSmoking-related cancers included lip, oral cavity, nasal cavity, pharynx, larynx, and esophagus, pancreas, kidney and bladder cancers that were prior to a diagnosis of lung cancer

Abbreviations: COPD, chronic obstructive pulmonary disease

Characteristics of the Study Population aIncome is lower than the level required for charging premium bSmoking-related cancers included lip, oral cavity, nasal cavity, pharynx, larynx, and esophagus, pancreas, kidney and bladder cancers that were prior to a diagnosis of lung cancer Abbreviations: COPD, chronic obstructive pulmonary disease In Table 2, Cox regression analysis revealed a significantly high incidence of lung cancer in male patients with COPD (HR, 1.56; 95 % confidence interval [CI], 1.51–1.61), asthma (HR, 1.36; 95 % CI, 1.30–1.41), TB (HR, 1.35; 95 % CI, 1.26–1.44), low income (HR, 1.14; 95 % CI, 1.05–1.23), hyperlipidemia (HR, 1.07; 95%CI, 1.04–1.11), and smoking-related cancer (HR, 1.79; 95 % CI, 1.68–1.90). The risk of lung cancer was high in female patients with TB (HR, 1.97; 95 % CI, 1.73–2.24), COPD (HR, 1.33; 95 % CI, 1.26–1.41), asthma (HR, 1.26; 95 % CI, 1.18–1.34), low income (HR, 1.36; 95 % CI, 1.20–1.54), hyperlipidemia (HR, 1.13; 95 % CI, 1.07–1.19), and smoking related cancer (HR, 2.28; 95 % CI, 2.02–2.57).
Table 2

Hazard Ratios and 95 % Confidence Intervals of Lung Cancer Stratified by Sex

MaleFemale
HR (95 % CI)P valueHR (95 % CI)P value
Lung diseases
 Tuberculosis1.35 (1.26–1.44)< 0.0011.97 (1.73–2.24)<0.001
 Asthma1.36 (1.30–1.41)< 0.0011.26 (1.18–1.34)<0.001
 COPD1.56 (1.51–1.61)< 0.0011.33 (1.26–1.41)<0.001
Low incomea1.14 (1.05–1.23)0.0011.36 (1.20–1.54)< 0.001
Age group
 20–390.14 (0.13–0.16)< 0.0010.15 (0.14–0.17)< 0.001
 40–49ReferenceReference
 50–592.80 (2.65–2.96)< 0.0012.17 (2.03–2.31)< 0.001
 60–697.30 (6.93–7.69)< 0.0014.35 (4.07–4.65)< 0.001
 70–7912.70 (12.08–13.34)< 0.0016.70 (6.26–7.16)< 0.001
 ≧808.91 (8.43–9.43)< 0.0015.72 (5.30–6.17)< 0.001
Comorbidities
 Diabetes1.00 (0.96–1.04)0.9261.01 (0.96–1.07)0.689
 Hyperlipidemia1.07 (1.04–1.11)<0.0011.13 (1.07–1.19)<0.001
 Chronic kidney disease0.90 (0.84–0.97)0.0040.87 (0.76–0.99)0.035
 Smoking–related cancersb1.79 (1.68–1.90)<0.0012.28 (2.02–2.57)<0.001

Adjustments were made to estimate HRs for all covariates (lung diseases, low income, age, comorbidities, urbanization and geographic area)

aIncome is lower than the level required for charging premium

bSmoking-related cancers included lip, oral cavity, nasal cavity, pharynx, larynx, and esophagus, pancreas, kidney and bladder cancers that were prior to a diagnosis of lung cancer

Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio

Hazard Ratios and 95 % Confidence Intervals of Lung Cancer Stratified by Sex Adjustments were made to estimate HRs for all covariates (lung diseases, low income, age, comorbidities, urbanization and geographic area) aIncome is lower than the level required for charging premium bSmoking-related cancers included lip, oral cavity, nasal cavity, pharynx, larynx, and esophagus, pancreas, kidney and bladder cancers that were prior to a diagnosis of lung cancer Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio Table 3 presents the adjusted HRs for SqCC stratified by sex. The incidence of SqCC was high in male patients with COPD (HR, 1.66; 95 % CI, 1.56–1.76), asthma (HR, 1.52; 95 % CI, 1.42–1.64), TB (HR, 1.37; 95 % CI, 1.21–1.54), and smoking-related cancer (HR, 2.58; 95 % CI, 2.33–2.86). The HRs of SqCC in women with TB, asthma, COPD, and smoking-related cancer were 2.10 (95 % CI, 1.36–3.23), 1.50 (95 % CI, 1.21–1.85), 1.44 (95 % CI, 1.19–1.74), and 3.98 (95 % CI, 2.84–5.57), respectively.
Table 3

Hazard Ratios and 95 % Confidence Intervals of Squamous Cell Carcinoma Stratified by Sex

MaleFemale
HR (95 % CI)P valueHR (95 % CI)P value
Lung diseases
 Tuberculosis1.37 (1.21–1.54)< 0.0012.10 (1.36–3.23)<0.001
 Asthma1.52 (1.42–1.64)< 0.0011.50 (1.21–1.85)<0.001
 COPD1.66 (1.56–1.76)< 0.0011.44 (1.19–1.74)<0.001
Low incomea1.15 (0.99–1.34)0.0662.35 (1.66–3.32)<0.001
Age group
 20–390.12 (0.09–0.15)< 0.0010.14 (0.09–0.20)<0.001
 40–49ReferenceReference
 50–593.59 (3.16–4.08)< 0.0012.05 (1.62–2.59)<0.001
 60–6912.38 (10.98–13.95)< 0.0014.47 (3.54–5.65)<0.001
70–7921.39 (19.03–24.04)< 0.0016.23 (4.89–7.92)<0.001
 ≧8013.36 (11.74–15.19)< 0.0014.66 (3.51–6.19)<0.001
Comorbidities
 Diabetes1.00 (0.93–1.07)0.9221.14 (0.94–1.39)0.169
 Hyperlipidemia0.98 (0.92–1.06)0.6680.97 (0.80–1.17)0.717
 Chronic kidney disease0.85 (0.73–0.97)0.0200.85 (0.53–1.34)0.473
 Smoking–related cancersb2.58 (2.33–2.86)< 0.0013.98 (2.84–5.57)<0.001

Adjustments were made to estimate HRs for all covariates (lung diseases, low income, age, comorbidities, urbanization and geographic area)

aIncome is lower than the level required for charging premium

bSmoking-related cancers included lip, oral cavity, nasal cavity, pharynx, larynx, and esophagus, pancreas, kidney and bladder cancers that were prior to a diagnosis of lung cancer

Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio

Hazard Ratios and 95 % Confidence Intervals of Squamous Cell Carcinoma Stratified by Sex Adjustments were made to estimate HRs for all covariates (lung diseases, low income, age, comorbidities, urbanization and geographic area) aIncome is lower than the level required for charging premium bSmoking-related cancers included lip, oral cavity, nasal cavity, pharynx, larynx, and esophagus, pancreas, kidney and bladder cancers that were prior to a diagnosis of lung cancer Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio Table 4 provides the HRs of adenocarcinoma stratified by sex. The risk of adenocarcinoma was high in male patients with COPD (HR, 1.50; 95 % CI, 1.42–1.59), TB (HR, 1.33; 95 % CI, 1.19–1.50), asthma (HR, 1.13; 95 % CI, 1.05–1.21), hyperlipidemia (HR, 1.19; 95 % CI, 1.12–1.26), and smoking-related cancer (HR, 1.46; 95 % CI, 1.30–1.63). The HRs of adenocarcinoma in female patients with TB, COPD, asthma, hyperlipidemia, and smoking-related cancer were 1.86 (95 % CI, 1.57–2.19), 1.33 (95 % CI, 1.25–1.42), 1.18 (95 % CI, 1.09–1.28), 1.19 (95 % CI, 1.12–1.26), and 2.00 (95 % CI, 1.71–2.35), respectively.
Table 4

Hazard Ratios and 95 % Confidence Intervals of Adenocarcinoma Stratified by Sex

Male
HR (95 % CI)P valueHR (95 % CI)P value
Lung diseases
 Tuberculosis1.33 (1.19–1.50)< 0.0011.86 (1.57–2.19)< 0.001
 Asthma1.13 (1.05–1.21)< 0.0011.18 (1.09–1.28)< 0.001
 COPD1.50 (1.42–1.59)< 0.0011.33 (1.25–1.42)< 0.001
Low incomea1.07 (0.94–1.22)0.3221.18 (1.00–1.39)0.055
Age group
 20–390.15 (0.13–0.17)< 0.0010.15 (0.13–0.17)< 0.001
 40–49ReferenceReference
 50–592.45 (2.27–2.64)< 0.0012.17 (2.01–2.34)< 0.001
 60–695.23 (4.85–5.63)< 0.0014.10 (3.80–4.44)< 0.001
 70–798.15 (7.59–8.76)< 0.0015.93 (5.46–6.43)< 0.001
 ≧805.61 (5.15–6.11)< 0.0014.03 (3.64–4.45)< 0.001
Comorbidities
 Diabetes0.95 (0.90–1.01)0.1060.95 (0.89–1.02)0.128
 Hyperlipidemia1.19 (1.12–1.26)< 0.0011.19 (1.12–1.26)< 0.001
 Chronic kidney disease0.86 (0.76–0.98)0.0190.84 (0.71–0.99)0.040
 Smoking–related cancersb1.46 (1.30–1.63)<0.0012.00 (1.71–2.35)< 0.001

Adjustments were made to estimate HRs for all covariates (lung diseases, low income, age, comorbidities, urbanization and geographic area)

aIncome is lower than the level required for charging premium

bSmoking-related cancers included lip, oral cavity, nasal cavity, pharynx, larynx, and esophagus, pancreas, kidney and bladder cancers that were prior to a diagnosis of lung cancer

Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio

Hazard Ratios and 95 % Confidence Intervals of Adenocarcinoma Stratified by Sex Adjustments were made to estimate HRs for all covariates (lung diseases, low income, age, comorbidities, urbanization and geographic area) aIncome is lower than the level required for charging premium bSmoking-related cancers included lip, oral cavity, nasal cavity, pharynx, larynx, and esophagus, pancreas, kidney and bladder cancers that were prior to a diagnosis of lung cancer Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio Table 5 displays the adjusted HRs of SmCC stratified by sex. The risk of SmCC was high in male patients with asthma (HR, 1.51; 95 % CI, 1.35–1.69), COPD (HR, 1.39; 95 % CI, 1.26–1.53), TB (HR, 1.24; 95 % CI, 1.01–1.52), and smoking-related cancer (HR, 1.35; 95 % CI, 1.10–1.66). The HRs of SmCC in women with TB, COPD, asthma, and smoking-related cancer were 2.23 (95 % CI, 1.17–4.25), 1.78 (95 % CI, 1.33–2.39), 1.63 (95 % CI, 1.16–2.27), and 3.71 (95 % CI, 2.12–6.49), respectively.
Table 5

Hazard Ratios and 95 % Confidence Intervals of Small Cell Carcinoma by Stratified by Sex

MaleFemale
HR (95 % CI)P valueHR (95 % CI)P value
Lung diseases
 Tuberculosis1.24 (1.01–1.52)0.0372.23 (1.17–4.25)0.015
 Asthma1.51 (1.35–1.69)< 0.0011.63 (1.16–2.27)0.005
 COPD1.39 (1.26–1.53)< 0.0011.78 (1.33–2.39)<0.001
Low incomea0.96 (0.75–1.23)0.7382.91 (1.80–4.68)< 0.001
Age group
 20–390.09 (0.06–0.12)< 0.0010.10 (0.04–0.27)< 0.001
 40–49ReferenceReference
 50–593.47 (2.93–4.10)< 0.0013.73 (2.31–6.01)< 0.001
 60–6910.60 (9.04–12.43)< 0.00110.86 (6.80–17.33)< 0.001
 70–7917.1 (14.64–19.98)< 0.00114.19 (8.73–23.07)< 0.001
 ≧809.61 (8.03–11.49)< 0.00114.97 (8.97–24.97)< 0.001
Comorbidities
 Diabetes1.07 (0.96–1.18)0.2261.24 (0.92–1.69)0.162
 Hyperlipidemia1.09 (0.98–1.21)0.1000.84 (0.61–1.15)0.264
 Chronic kidney disease0.70 (0.55–0.89)0.0030.90 (0.44–1.84)0.774
 Smoking-related cancersb1.35 (1.10–1.66)0.0043.71 (2.12–6.49)< 0.001

Adjustments were made to estimate HRs for all covariates (lung diseases, low income, age, comorbidities, urbanization and geographic area)

aIncome is lower than the level required for charging premium

bSmoking-related cancers included lip, oral cavity, nasal cavity, pharynx, larynx, and esophagus, pancreas, kidney and bladder cancers that were prior to a diagnosis of lung cancer

Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio

Hazard Ratios and 95 % Confidence Intervals of Small Cell Carcinoma by Stratified by Sex Adjustments were made to estimate HRs for all covariates (lung diseases, low income, age, comorbidities, urbanization and geographic area) aIncome is lower than the level required for charging premium bSmoking-related cancers included lip, oral cavity, nasal cavity, pharynx, larynx, and esophagus, pancreas, kidney and bladder cancers that were prior to a diagnosis of lung cancer Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio

Discussion

This study demonstrated that male and female patients with TB, asthma, and COPD had increased risks of lung SqCC, adenocarcinoma, and SmCC. Determining risk factors for specific types of lung cancer can help physicians gain a detailed understanding of the etiology of lung cancer and therefore identify the high-risk population for screening. To the best of our knowledge, no study has investigated the association between pulmonary diseases and histologic types of lung cancer. According to the study results, heterogeneity was observed in the risk factors for lung cancer and the different histologic types in male and female patients. A population-based, case-control study of female nonsmokers revealed an increased risk of lung cancer in patients with TB who were diagnosed before the age of 21 years [29]. The incidence rate ratio of lung cancer in the TB cohorts was 1.98 (95%CI, 1.37–2.83) 2 – 4 years after TB infection [12]. A hospital-based, case-control study involving interviews of 226 female nonsmokers with lung cancer and 279 controls demonstrated that TB increased the risk of lung cancer (odds ratio [OR], 4.7; 95 % CI, 1.6–13.2) [30]. Yu et al. found an increased risk of lung cancer among patients with TB (HR, 3.32; 95 % CI, 2.70–4.09), which was higher than that of COPD (HR, 2.30; 95 % CI, 2.07–2.55) [28]. A systematic review identified a direct relationship between preexisting TB and lung cancer, particularly adenocarcinoma (relative risk [RR], 1.6; 95 % CI, 1.2–2.1) [18]. A study conducted in Taiwan demonstrated that TB was an independent risk factor for SqCC, SmCC, and adenocarcinoma in men and women [6]. Such an association is particularly crucial in Taiwan, where the prevalence of TB is high [31, 32]. Compared with asthma and COPD, TB appears to have a stronger association with lung cancer among women. Additional studies are necessary to assess the possible mechanisms of this association. In this study, COPD was associated with the risk of the major types of lung cancer. Chronic airway inflammation is a major risk factor for COPD and is also associated with an increased risk of lung cancer [13]. A study involving the 22-year follow-up of 5,402 participants concluded that moderate-to-severe obstructive pulmonary disease was associated with a higher risk of incident lung cancer (HR, 2.8; 95 % CI, 1.8–4.4) [33]. Denholm et al. found that chronic bronchitis and emphysema were positively associated with lung cancer after adjusting for other respiratory diseases and smoking (OR, 1.33; 95 % CI, 1.20–1.48 for men; OR, 1.50; 95 % CI, 1.21–1.87 for women) [34]. The prevalence of smoking is almost 10-fold higher in Taiwanese men than that in women [35]. However, the smoking status of the study population was not available. This may be the reason for the observed differences between men and women. Chronic bronchitis and emphysema increased the risk of SqCC (HR, 1.54; 95 % CI, 1.09–2.18) independent of smoking [36]. COPD also increased the risk of SqCC in smokers [13]. Pesch et al. performed a pooled analysis of case-control studies including 13,169 cases and 16,010 controls from Europe and Canada [37]. Their analysis demonstrated that adenocarcinoma was the most prevalent subtype in never-smokers and women. The ORs were elevated for exposure to cigarette smoke and were higher for SqCC and SmCC than for adenocarcinoma. Freedman et al. recruited 279,214 men and 184,623 women aged 50–71 years from eight states in the United States to evaluate whether women were more susceptible to lung cancer caused by cigarette smoking than men [38]. Their results illustrated that the HRs of adenocarcinoma, SmCC, and undifferentiated tumors were similar between men and women among ex-smokers and current smokers. However, among current smokers, the HR of SqCC in men was approximately 2-fold higher than that in women. This study also suggests that patients with asthma are at an increased risk of three histological types (SqCC, adenocarcinoma, and SmCC) of lung cancer. Asthma is one of the most common chronic airway diseases and affects 300 million people of all ages and ethnicities [39]. In Taiwan, the prevalence of asthma has increased to 11.9 % [40]. Because asthma causes complex chronic airway inflammation, it has been hypothesized to lead to carcinogenesis [8]. Case-control studies have produced varied results for the association between asthma and lung cancer [41, 42]. In a Swedish cohort with a hospital-discharge diagnosis of asthma, the standardized incidence rate ratio of lung cancer was 1.51 in men (95 % CI, 1.38–1.65) and 1.78 in women (95 % CI, 1.55–2.03), and the risk of histologic types of lung cancer was higher in patients with SqCC and SmCC [16]. In a meta-analysis, the RRs were 1.69 (95 % CI, 1.26–2.26) for SqCC, 1.71 (95 % CI, 0.99–2.95) for SmCC, and 1.09 (95 % CI, 0.88–1.36) for adenocarcinoma [15]. In this study, hyperlipidemia was also associated with an increased risk of adenocarcinoma. Hyperlipidemia is a component of metabolic syndrome and is associated with insulin resistance [43]. Hyperinsulinemia, hyperglycemia, and chronic inflammation play a vital role in the neoplastic process [44]. High serum triglyceride concentrations are associated with an increased risk of lung cancer (fourth vs first quartile: HR, 1.94; 95 % CI, 1.47–2.54) [22]. Additional studies are required to assess the association between hyperlipidemia and adenocarcinoma. Evaluating the temporal relationship between pulmonary diseases and subsequent lung cancer in case-control studies is difficult. Previous studies might have yielded inconclusive results because they focused mainly on the high-risk populations of heavy smokers. This study has several strengths. First, our data were retrieved from combined databases (NHIRD, TCRD and NDRD) that included all residents; hence, recall and selection bias was minimized. Second, the histologic type of lung cancer was confirmed using the TCRD. Nevertheless, our study has some limitations. First, the NHIRD does not contain detailed clinical data and information on lifestyle-related factors such as smoking, obesity, physical inactivity, dietary habits, and family history, which are closely associated with lung cancer. Smoking is a major confounding factor of lung cancer. Biases were minimized by adjusting for COPD and smoking-related cancer. Second, patients with asthma, COPD, and TB may have used medications that may have complicated their conditions. This study did not evaluate the effects of drugs.

Conclusions

This study demonstrated that asthma, COPD, and TB were associated with increased risks of all major subtypes of lung cancer. The risk was the highest among women with TB.
  44 in total

1.  HDL-cholesterol and the incidence of lung cancer in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Anna M Kucharska-Newton; Wayne D Rosamond; Jane C Schroeder; Ann Marie McNeill; Josef Coresh; Aaron R Folsom
Journal:  Lung Cancer       Date:  2008-03-14       Impact factor: 5.705

2.  Total cholesterol and cancer risk in a large prospective study in Korea.

Authors:  Cari M Kitahara; Amy Berrington de González; Neal D Freedman; Rachel Huxley; Yejin Mok; Sun Ha Jee; Jonathan M Samet
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

3.  Hormone replacement therapy and lung cancer risk in Chinese.

Authors:  Kuan-Yu Chen; Chin-Fu Hsiao; Gee-Chen Chang; Yin-Huang Tsai; Wu-Chou Su; Reury-Perng Perng; Ming-Shyan Huang; Chao A Hsiung; Chien-Jen Chen; Pan-Chyr Yang
Journal:  Cancer       Date:  2007-10-15       Impact factor: 6.860

4.  Diagnosis and treatment delay among pulmonary tuberculosis patients identified using the Taiwan reporting enquiry system, 2002-2006.

Authors:  Hui-Ping Lin; Chung-Yeh Deng; Pesus Chou
Journal:  BMC Public Health       Date:  2009-02-12       Impact factor: 3.295

5.  Gender differences in smoking behaviors in an Asian population.

Authors:  Yi-Wen Tsai; Tzu-I Tsai; Chung-Lin Yang; Ken N Kuo
Journal:  J Womens Health (Larchmt)       Date:  2008 Jul-Aug       Impact factor: 2.681

6.  Risk of lung cancer following nonmalignant respiratory conditions among nonsmoking women living in Shenyang, Northeast China.

Authors:  Huiying Liang; Peng Guan; Zhihua Yin; Xuelian Li; Qincheng He; Baosen Zhou
Journal:  J Womens Health (Larchmt)       Date:  2009-12       Impact factor: 2.681

7.  Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study.

Authors:  Neal D Freedman; Michael F Leitzmann; Albert R Hollenbeck; Arthur Schatzkin; Christian C Abnet
Journal:  Lancet Oncol       Date:  2008-06-13       Impact factor: 41.316

Review 8.  Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: a systematic review.

Authors:  Hui-Ying Liang; Xue-Lian Li; Xiao-Song Yu; Peng Guan; Zhi-Hua Yin; Qin-Cheng He; Bao-Sen Zhou
Journal:  Int J Cancer       Date:  2009-12-15       Impact factor: 7.396

9.  COPD prevalence is increased in lung cancer, independent of age, sex and smoking history.

Authors:  R P Young; R J Hopkins; T Christmas; P N Black; P Metcalf; G D Gamble
Journal:  Eur Respir J       Date:  2009-02-05       Impact factor: 16.671

10.  Serum triglyceride concentrations and cancer risk in a large cohort study in Austria.

Authors:  H Ulmer; W Borena; K Rapp; J Klenk; A Strasak; G Diem; H Concin; G Nagel
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more
  13 in total

1.  Chrysophanol exhibits anti-cancer activities in lung cancer cell through regulating ROS/HIF-1a/VEGF signaling pathway.

Authors:  Jie Zhang; Qian Wang; Qiang Wang; Peng Guo; Yong Wang; Yuqing Xing; Mengmeng Zhang; Fujun Liu; Qingyun Zeng
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-10-26       Impact factor: 3.000

2.  Post-inhaled corticosteroid pulmonary tuberculosis and pneumonia increases lung cancer in patients with COPD.

Authors:  Ming-Fang Wu; Zhi-Hong Jian; Jing-Yang Huang; Cheng-Feng Jan; Oswald Ndi Nfor; Kai-Ming Jhang; Wen-Yuan Ku; Chien-Chang Ho; Chia-Chi Lung; Hui-Hsien Pan; Min-Chen Wu; Yung-Po Liaw
Journal:  BMC Cancer       Date:  2016-10-10       Impact factor: 4.430

3.  Asthma and the risk of lung cancer: a meta-analysis.

Authors:  Yan-Liang Qu; Jun Liu; Li-Xin Zhang; Chun-Min Wu; Ai-Jie Chu; Bao-Lei Wen; Chao Ma; Xu-Yan Yan; Xin Zhang; De-Ming Wang; Xin Lv; Shu-Jian Hou
Journal:  Oncotarget       Date:  2017-02-14

4.  snoRNA and piRNA expression levels modified by tobacco use in women with lung adenocarcinoma.

Authors:  Natasha Andressa Nogueira Jorge; Gabriel Wajnberg; Carlos Gil Ferreira; Benilton de Sa Carvalho; Fabio Passetti
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

5.  Effects of age on the association between pulmonary tuberculosis and lung cancer in a South Korean cohort.

Authors:  Soo Jeong An; Young-Ju Kim; Seon-Sook Han; Jeongwon Heo
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 2.895

6.  The use of corticosteroids in patients with COPD or asthma does not decrease lung squamous cell carcinoma.

Authors:  Zhi-Hong Jian; Jing-Yang Huang; Frank Cheau-Feng Lin; Oswald Ndi Nfor; Kai-Ming Jhang; Wen-Yuan Ku; Chien-Chang Ho; Chia-Chi Lung; Hui-Hsien Pan; Yu-Chiu Liang; Ming-Fang Wu; Yung-Po Liaw
Journal:  BMC Pulm Med       Date:  2015-12-03       Impact factor: 3.317

7.  Post-Inhaled Corticosteroid Pulmonary Tuberculosis Increases Lung Cancer in Patients with Asthma.

Authors:  Zhi-Hong Jian; Jing-Yang Huang; Frank Cheau-Feng Lin; Oswald Ndi Nfor; Kai-Ming Jhang; Wen-Yuan Ku; Chien-Chang Ho; Chia-Chi Lung; Hui-Hsien Pan; Min-Chen Wu; Ming-Fang Wu; Yung-Po Liaw
Journal:  PLoS One       Date:  2016-07-22       Impact factor: 3.240

8.  The link between chronic obstructive pulmonary disease phenotypes and histological subtypes of lung cancer: a case-control study.

Authors:  Wei Wang; Mengshuang Xie; Shuang Dou; Liwei Cui; Chunyan Zheng; Wei Xiao
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-04-13

9.  The association between COPD and outcomes of patients with advanced chronic kidney disease.

Authors:  Chih-Cheng Lai; Che-Hsiung Wu; Ya-Hui Wang; Cheng-Yi Wang; Vin-Cent Wu; Likwang Chen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-09-17

10.  Long-Term Outcomes in Patients with Incident Chronic Obstructive Pulmonary Disease after Acute Kidney Injury: A Competing-Risk Analysis of a Nationwide Cohort.

Authors:  Che-Hsiung Wu; Huang-Ming Chang; Cheng-Yi Wang; Likwang Chen; Liang-Wen Chen; Chien-Heng Lai; Shuenn-Wen Kuo; Hao-Chien Wang; Vin-Cent Wu
Journal:  J Clin Med       Date:  2018-08-24       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.